Sarecycline Truncal Acne Safety and Efficacy Response (TASER)

Angela Moore

Status: Completed

Conditions: Acne Vulgaris

Treatments: Drug: Sarecycline

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT05010538

Sarecycline TASER1

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and safety of oral sarecycline 1.5 mg/kg/day in truncal acne. Patients with moderate to severe acne vulgaris will be observed over a period of 12 weeks. Lesion counts, investigator's global assessments, photography, and safety measures will be assessed for the trunk and face.

Enrollment: 10 patients

Sex: All

Ages: 9 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female age 9 or above.
• Clinical diagnosis of moderate to severe truncal acne based on IGA

Exclusion criteria

• Known or suspected allergies or sensitivities to any components of the study drug.
• Any disorders that would preclude the use of tetracycline-class antibiotics or sarecycline.
• Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the Investigator's judgment) if the subject takes part in the trial.

Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

10 participants in 1 patient group

Sarecycline

Description:

Eligible patients will be prescribed with commercially available sarecycline at a dosage of 1.5 mg/kg/day and followed for 12 weeks post initiation of treatment.

Treatment:

Drug: Sarecycline